Phio Pharmaceuticals Corp. Reports Material Event

Phio Pharmaceuticals (PHIO) filed an 8-K announcing board changes.

Rhea-AI Filing Summary

Phio Pharmaceuticals (PHIO) filed an 8-K announcing board changes. On October 31, 2025, Robert Ferrara resigned from the Board, the Compensation and Audit Committees, and as Lead Independent Director, effective immediately. The company states his decision to resign was not the result of any disagreement with the company.

Pursuant to the Governance Committee’s recommendation and following the resignation, the Board reduced its size from six to five members, leaving no vacancies. The company also announced the appointment of David Deming as Lead Independent Director in a press release issued on October 31, 2025, which is furnished as Exhibit 99.1.

Insights

Corporate Governance Analyst

Board leadership change with immediate replacement; governance continuity appears maintained, impact likely neutral.

PHIO Pharmaceuticals Corp. reported that Robert Ferrara resigned from the Board effective October 31, 2025, including his roles on the Compensation and Audit Committees and as Lead Independent Director. The Board concurrently reduced its size from six to five members, leaving no vacancies. The company announced David Deming as the new Lead Independent Director on October 31, 2025 (Exhibit 99.1). The filing states the resignation was not due to a disagreement with the company.

The immediate leadership designation helps preserve board oversight continuity. Reducing the board size concentrates responsibilities among fewer directors, which can streamline decisions but may also increase individual workload. The absence of a disclosed disagreement reduces concerns about internal conflict behind the change.

Watch for updates on committee compositions following Mr. Ferrara’s departure, as Audit and Compensation oversight roles are critical. Any subsequent 8‑K or proxy disclosure clarifying committee assignments and independence mix will be informative over the next few reporting periods.

8-K Event Classification

3 items: 5.02, 8.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/31/2025 - 10:30 AM EDT Learn about SEC filing dates

false 0001533040 0001533040 2025-10-31 2025-10-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported):  October 31, 2025

PHIO PHARMACEUTICALS CORP.

(Exact name of registrant as specified in its charter)

Delaware	001-36304	45-3215903
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

411 Swedeland Road, Suite 23-1080
King of Prussia, PA	19406
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (610) 947-0251

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s):		Name of each exchange on which registered:
Common Stock, par value $0.0001 per share		PHIO		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 31, 2025, Robert Ferrara resigned, effective immediately, from his position as a director of Phio Pharmaceutical Corp.’s (the “Company’s”) Board of Directors (the “Board”), including his memberships on the Compensation Committee and the Audit Committee, and as Lead Independent Director of the Board. His decision to resign from the Board was not the result of any disagreement with the Company. 

Pursuant to the recommendation of the Governance Committee and in connection with Mr. Ferrara’s resignation, the Board reduced the size of the Board from six (6) to five (5) members. As a result of such reduction, there are currently no vacancies on the Board.

Item 8.01. Other Events.

On October 31, 2025, the Company issued a press release announcing the appointment of David Deming as Lead Independent Director of the Board.

The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued by the Company on October 31, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PHIO PHARMACEUTICALS CORP.
Date: October 31, 2025	By:	/s/ Robert J. Bitterman
		Robert J. Bitterman President & Chief Executive Officer

3